![]() ![]() Based on the underlying science on the role of CDK2 inhibition in cancer, and the potential for this mechanism to impact large populations of patients, BLU-222 represents one of the most important programs within Blueprint Medicines' early clinical development pipeline. ![]() The datasets represent a diversity of fundamental value drivers in our clinical portfolio, which create opportunities to substantially expand our patient impact and highlight our ambition to deliver many more transformational medicines to patients in the future."ĬDK2 is a cell cycle regulator and important cancer target across a broad range of malignancies, including HR+/HER2- breast cancer. "Together, these presentations reflect how we are developing differentiated, highly selective therapies against promising disease targets, and demonstrate strong execution in advancing potential treatment options for large patient populations, including HR+/HER2- breast cancer and EGFR-mutant lung cancer. "At ASCO, we are reporting early clinical data for three therapeutic candidates highlighting the breadth of our pipeline, which lays the foundation for our next wave of precision therapy programs to tackle significant medical challenges," said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. The presentations showcase the company's progress in developing precision therapies to address the needs of broad patient populations, including hormone-receptor-positive/HER2-negative (HR+/HER2-) breast cancer and EGFR-mutant non-small cell lung cancer (NSCLC). Breadth of pipeline featured in multiple early clinical data presentations, reflecting diversity of fundamental growth drivers across development programs -ĬAMBRIDGE, Mass., J/PRNewswire/ - Blueprint Medicines Corporation (Nasdaq: BPMC) today announced clinical data for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |